Balstilimab
Balstilimab is a pharmaceutical drug with 38 clinical trials. Currently 27 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
23
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
20.0%
1 of 5 finished
80.0%
4 ended early
27
trials recruiting
38
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Clinical Trials (38)
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Botensilimab and Balstilimab Optimization in Colorectal Cancer
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 38